The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs.
 
David Granger
Employment - NovalGen
Stock and Other Ownership Interests - Crescendo Biologics; GlaxoSmithKline; NovalGen
Research Funding - NovalGen
Travel, Accommodations, Expenses - NovalGen
 
Micaela Harrasser
No Relationships to Disclose
 
Rachel Evans
Research Funding - AstraZeneca/MedImmune (Inst)
 
Vincent Muczynski
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
Research Funding - NovalGen
 
Kerry Chester
Employment - NovalGen
Stock and Other Ownership Interests - NovalGen
Consulting or Advisory Role - NovalGen
Patents, Royalties, Other Intellectual Property - I am an inventor on antibody patents filed by UCL Business Ltd, The Network Building, 97 Tottenham Court Road, London W1T 4TP, UK
Expert Testimony - Allen & Overy LLP
 
Amit C. Nathwani
Employment - Freeline Therapeutics; NovalGen
Leadership - Freeline Therapeutics; NovalGen
Stock and Other Ownership Interests - Freeline Therapeutics; NovalGen
Research Funding - Biomarin
Patents, Royalties, Other Intellectual Property - Revenue share agreement with St Jude for LP1-FIX licence Revenue share agreement with UCL for FVIII licence and technology licenced to Freeline and Novalgen